Akero Announces Strongly Positive Histological Data Across All Efruxifermin Dose Groups in 16-Week Phase 2a BALANCED Study in NASH Patients
48% fibrosis improvement of at least one stage without worsening of NAS across all dose groups, with a 62% response rate for the 50mg dose group28% fibrosis improvement of at least two stages across all dose groups, with a 38% response rate for the 50mg dose group48% NASH resolution without worsening of fibrosis across all […]
